HEADER TRANSPORT PROTEIN/INHIBITOR 10-SEP-11 2LJC TITLE STRUCTURE OF THE INFLUENZA AM2-BM2 CHIMERIC CHANNEL BOUND TO TITLE 2 RIMANTADINE COMPND MOL_ID: 1; COMPND 2 MOLECULE: M2 PROTEIN, BM2 PROTEIN CHIMERA; COMPND 3 CHAIN: A, B, C, D; COMPND 4 ENGINEERED: YES; COMPND 5 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: INFLUENZA A VIRUS, INFLUENZA B VIRUS; SOURCE 3 ORGANISM_TAXID: 41857, 529646; SOURCE 4 STRAIN: H3N2, B/TAIWAN/70061/2006; SOURCE 5 GENE: BM2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR: TRPLE-FUSION KEYWDS M2 CHANNEL, RIMANTADINE BINDING, DRUG COMPLEX, TRANSPORT PROTEIN, KEYWDS 2 TRANSPORT PROTEIN-INHIBITOR COMPLEX EXPDTA SOLUTION NMR NUMMDL 15 AUTHOR R.M.PIELAK,K.OXENOID,J.J.CHOU REVDAT 3 01-MAY-24 2LJC 1 REMARK SEQADV REVDAT 2 21-MAR-12 2LJC 1 JRNL REVDAT 1 16-NOV-11 2LJC 0 JRNL AUTH R.M.PIELAK,K.OXENOID,J.J.CHOU JRNL TITL STRUCTURAL INVESTIGATION OF RIMANTADINE INHIBITION OF THE JRNL TITL 2 AM2-BM2 CHIMERA CHANNEL OF INFLUENZA VIRUSES. JRNL REF STRUCTURE V. 19 1655 2011 JRNL REFN ISSN 0969-2126 JRNL PMID 22078564 JRNL DOI 10.1016/J.STR.2011.09.003 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : XWINNMR, X-PLOR NIH REMARK 3 AUTHORS : BRUKER BIOSPIN (XWINNMR), SCHWIETERS, KUSZEWSKI, REMARK 3 TJANDRA AND CLORE (X-PLOR NIH) REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2LJC COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 20-SEP-11. REMARK 100 THE DEPOSITION ID IS D_1000102452. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 303 REMARK 210 PH : 7.5 REMARK 210 IONIC STRENGTH : 100 REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 1.2 MM [U-100% 13C; U-100% 15N; REMARK 210 U-80% 2H] AM2-BM2 PEPTIDE, 300 REMARK 210 MM DHPC, 40 MM SODIUM PHOSPHATE, REMARK 210 50 MM RIMANTADINE, 95% H2O/5% REMARK 210 D2O; 1.5 MM [U-100% 13C; U-100% REMARK 210 15N] AM2-BM2 PEPTIDE, 300 MM [U- REMARK 210 99% 2H] DHPC, 40 MM SODIUM REMARK 210 PHOSPHATE, 50 MM RIMANTADINE, 95% REMARK 210 H2O/5% D2O; 1.5 MM [U-100% 15N; REMARK 210 U-99% 2H] AM2-BM2 PEPTIDE, 300 REMARK 210 MM [U-99% 2H] DHPC, 40 MM SODIUM REMARK 210 PHOSPHATE, 50 MM RIMANTADINE, 95% REMARK 210 H2O/5% D2O; 0.9 MM [U-100% 15N; REMARK 210 U-99% 2H] AM2-BM2 PEPTIDE, 0.9 REMARK 210 MM [U-10% 13C] AM2-BM2 PEPTIDE, REMARK 210 300 MM [U-99% 2H] DHPC, 40 MM REMARK 210 SODIUM PHOSPHATE, 50 MM REMARK 210 RIMANTADINE, 95% H2O/5% D2O; 1.4 REMARK 210 MM [U-15% 13C] AM2-BM2 PEPTIDE, REMARK 210 300 MM [U-99% 2H] DHPC, 40 MM REMARK 210 SODIUM PHOSPHATE, 50 MM REMARK 210 RIMANTADINE, 95% H2O/5% D2O; 0.5 REMARK 210 MM [U-100% 13C; U-100% 15N; U-80% REMARK 210 2H] AM2-BM2 PEPTIDE, 300 MM REMARK 210 DHPC, 40 MM SODIUM PHOSPHATE, 50 REMARK 210 MM RIMANTADINE, 5.4 MG DNA REMARK 210 NANOTUBE, 95% H2O/5% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-15N HSQC; 2D 1H-13C HSQC; REMARK 210 3D HNCA; 3D 1H-15N NOESY; 3D 1H- REMARK 210 13C NOESY ALIPHATIC; 3D 1H-13C REMARK 210 NOESY AROMATIC; 2D 1H-13C HSQC REMARK 210 (28M CT); INTERLEAVED HSQC-TROSY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ REMARK 210 SPECTROMETER MODEL : DMX REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : CARA, X-PLOR NIH, NMRPIPE REMARK 210 METHOD USED : SIMULATED ANNEALING, MOLECULAR REMARK 210 DYNAMICS REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 75 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 15 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LOWEST REMARK 210 ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 465 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 MODELS 1-15 REMARK 465 RES C SSSEQI REMARK 465 ARG A 18 REMARK 465 SER A 19 REMARK 465 ASN A 20 REMARK 465 ASP A 21 REMARK 465 SER A 22 REMARK 465 ARG B 18 REMARK 465 SER B 19 REMARK 465 ASN B 20 REMARK 465 ASP B 21 REMARK 465 SER B 22 REMARK 465 ARG C 18 REMARK 465 SER C 19 REMARK 465 ASN C 20 REMARK 465 ASP C 21 REMARK 465 SER C 22 REMARK 465 ARG D 18 REMARK 465 SER D 19 REMARK 465 ASN D 20 REMARK 465 ASP D 21 REMARK 465 SER D 22 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (RES=RESIDUE NAME; REMARK 470 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 470 MODELS 1-15 REMARK 470 RES CSSEQI ATOMS REMARK 470 GLY A 52 O REMARK 470 GLY B 52 O REMARK 470 GLY C 52 O REMARK 470 GLY D 52 O REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 LYS A 50 -70.84 -58.87 REMARK 500 1 ARG A 51 96.86 -66.86 REMARK 500 1 ASP B 24 77.99 -154.13 REMARK 500 1 PRO B 25 78.28 -47.76 REMARK 500 1 ARG C 51 129.19 -171.39 REMARK 500 1 PRO D 25 69.03 -45.39 REMARK 500 1 ILE D 49 -83.99 -46.21 REMARK 500 1 ARG D 51 -70.28 63.78 REMARK 500 2 PRO A 25 -14.79 -49.42 REMARK 500 2 ASP B 24 71.57 -157.82 REMARK 500 2 PRO B 25 78.06 -44.32 REMARK 500 2 GLN B 48 -99.26 -37.19 REMARK 500 2 ASP C 24 54.71 39.82 REMARK 500 2 PRO D 25 72.52 -43.52 REMARK 500 2 ILE D 49 -72.90 -36.17 REMARK 500 2 ARG D 51 -72.92 61.01 REMARK 500 3 ASP B 24 76.70 -158.59 REMARK 500 3 PRO B 25 71.29 -53.30 REMARK 500 3 ASP C 24 53.31 39.32 REMARK 500 3 PRO D 25 73.42 -41.84 REMARK 500 3 ILE D 49 -72.68 -34.61 REMARK 500 3 ARG D 51 -73.45 60.23 REMARK 500 4 LYS A 50 -72.98 -82.44 REMARK 500 4 PRO B 25 78.81 -42.55 REMARK 500 4 GLN B 48 -75.82 -60.86 REMARK 500 4 ASP C 24 54.42 39.71 REMARK 500 4 PRO D 25 74.29 -42.96 REMARK 500 4 ILE D 49 -81.19 -39.98 REMARK 500 4 ARG D 51 -69.35 64.64 REMARK 500 5 ASP A 24 57.94 -157.09 REMARK 500 5 PRO B 25 80.63 -39.94 REMARK 500 5 GLN B 48 -87.42 -46.20 REMARK 500 5 ARG B 51 33.31 -90.05 REMARK 500 5 ILE C 49 -90.53 -179.67 REMARK 500 5 PRO D 25 73.52 -42.62 REMARK 500 5 ILE D 49 -86.93 -48.44 REMARK 500 5 ARG D 51 -70.11 65.26 REMARK 500 6 ASP A 24 58.80 76.26 REMARK 500 6 PRO A 25 9.32 -65.83 REMARK 500 6 LYS A 50 -71.58 -73.64 REMARK 500 6 PRO B 25 86.91 -39.50 REMARK 500 6 GLN B 48 -99.21 -38.88 REMARK 500 6 PRO D 25 75.89 -41.53 REMARK 500 6 ILE D 49 -81.25 -39.71 REMARK 500 6 ARG D 51 -70.71 65.90 REMARK 500 7 ASP A 24 61.22 79.66 REMARK 500 7 PRO A 25 9.46 -69.41 REMARK 500 7 ILE A 49 -68.13 153.57 REMARK 500 7 PRO B 25 85.36 -37.81 REMARK 500 7 GLN B 48 48.24 -65.16 REMARK 500 REMARK 500 THIS ENTRY HAS 121 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE RIM A 1 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2RLF RELATED DB: PDB REMARK 900 AM2 CHANNEL STRUCTURE REMARK 900 RELATED ID: 2KIX RELATED DB: PDB REMARK 900 BM2 CHANNEL STRUCTURE REMARK 900 RELATED ID: 2LJB RELATED DB: PDB REMARK 900 AM2-BM2 CHIMERIC CHANNEL WITHOUT DRUG REMARK 900 RELATED ID: 2KWX RELATED DB: PDB REMARK 900 V27A MUTANT REMARK 900 RELATED ID: 17929 RELATED DB: BMRB DBREF 2LJC A 18 37 UNP Q9YP62 Q9YP62_9INFA 18 37 DBREF 2LJC A 38 52 UNP B4UQM4 B4UQM4_9INFB 20 34 DBREF 2LJC B 18 37 UNP Q9YP62 Q9YP62_9INFA 18 37 DBREF 2LJC B 38 52 UNP B4UQM4 B4UQM4_9INFB 20 34 DBREF 2LJC C 18 37 UNP Q9YP62 Q9YP62_9INFA 18 37 DBREF 2LJC C 38 52 UNP B4UQM4 B4UQM4_9INFB 20 34 DBREF 2LJC D 18 37 UNP Q9YP62 Q9YP62_9INFA 18 37 DBREF 2LJC D 38 52 UNP B4UQM4 B4UQM4_9INFB 20 34 SEQADV 2LJC SER A 19 UNP Q9YP62 CYS 19 ENGINEERED MUTATION SEQADV 2LJC SER B 19 UNP Q9YP62 CYS 19 ENGINEERED MUTATION SEQADV 2LJC SER C 19 UNP Q9YP62 CYS 19 ENGINEERED MUTATION SEQADV 2LJC SER D 19 UNP Q9YP62 CYS 19 ENGINEERED MUTATION SEQRES 1 A 35 ARG SER ASN ASP SER SER ASP PRO LEU VAL VAL ALA ALA SEQRES 2 A 35 SER ILE ILE GLY ILE LEU HIS PHE ILE ALA TRP THR ILE SEQRES 3 A 35 GLY HIS LEU ASN GLN ILE LYS ARG GLY SEQRES 1 B 35 ARG SER ASN ASP SER SER ASP PRO LEU VAL VAL ALA ALA SEQRES 2 B 35 SER ILE ILE GLY ILE LEU HIS PHE ILE ALA TRP THR ILE SEQRES 3 B 35 GLY HIS LEU ASN GLN ILE LYS ARG GLY SEQRES 1 C 35 ARG SER ASN ASP SER SER ASP PRO LEU VAL VAL ALA ALA SEQRES 2 C 35 SER ILE ILE GLY ILE LEU HIS PHE ILE ALA TRP THR ILE SEQRES 3 C 35 GLY HIS LEU ASN GLN ILE LYS ARG GLY SEQRES 1 D 35 ARG SER ASN ASP SER SER ASP PRO LEU VAL VAL ALA ALA SEQRES 2 D 35 SER ILE ILE GLY ILE LEU HIS PHE ILE ALA TRP THR ILE SEQRES 3 D 35 GLY HIS LEU ASN GLN ILE LYS ARG GLY HET RIM A 1 34 HETNAM RIM RIMANTADINE HETSYN RIM 1-(1-ADAMANTYL)ETHANAMINE FORMUL 5 RIM C12 H21 N HELIX 1 1 ASP A 24 ARG A 51 1 28 HELIX 2 2 PRO B 25 GLY B 52 1 28 HELIX 3 3 ASP C 24 THR C 42 1 19 HELIX 4 4 HIS C 45 LYS C 50 1 6 HELIX 5 5 PRO D 25 LEU D 46 1 22 SITE 1 AC1 5 ALA A 30 ALA B 30 ALA C 30 ALA D 30 SITE 2 AC1 5 SER D 31 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1